Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
Unusual case of gastroparesis leading to severe gastromegaly with demyelinating disease as a rare cause.
Gait variability measures reveal differences between multiple sclerosis patients and healthy controls.
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Yield of emergent neuroimaging among children presenting with a first complex febrile seizure.
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis.
Fingolimod modulates microglial activation to augment markers of remyelination.
Daclizumab (anti-CD25) in multiple sclerosis.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Balance impairment in people with multiple sclerosis: Preliminary evidence for the Balance Evaluation Systems Test.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
2nd Annual Congress on Neurology and Epidemiology
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.

Pages